|
1
|
Deneka AY, Boumber Y, Beck T and Golemis
EA: Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic
Approach in Small Cell Lung Cancer (SCLC). Cancers (Basel).
11(1297)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liu L, Zhang X, Zhou L, Yang T, Qiao Y and
Jiang X: Carrelizumab combined with anlotinib in the treatment of
extensive-stage small cell lung cancer: A case report. Medicine
(Baltimore). 100(e27138)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Barrows ED, Blackburn MJ and Liu SV:
Evolving role of immunotherapy in small cell lung cancer. Semin
Cancer Biol. 86(Pt 3):868–874. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ando K, Manabe R, Kishino Y, Kusumoto S,
Yamaoka T, Tanaka A, Ohmori T, Ohnishi T and Sagara H: Comparative
Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1
Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung
Cancer: A Systematic Review and Network Meta-Analysis. Curr Oncol.
28:1094–1113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
He Y and An T: Toripalimab in an advanced
non-small cell lung cancer patient with poor general condition
after multiline treatment: A case report. J Int Med Res.
49(3000605211042988)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Moya-Horno I, Viteri S, Karachaliou N and
Rosell R: Combination of immunotherapy with targeted therapies in
advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol.
10(1758834017745012)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tian Y, Zhai X, Han A, Zhu H and Yu J:
Potential immune escape mechanisms underlying the distinct clinical
outcome of immune checkpoint blockades in small cell lung cancer. J
Hematol Oncol. 12(67)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gagnier JJ, Kienle G, Altman DG, Moher D,
Sox H and Riley D: CARE Group. The CARE guidelines: Consensus-based
clinical case reporting guideline development. Headache.
53:1541–1547. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Amin MB: American Joint Committee on
Cancer and American Cancer Society AJCC cancer staging manual. 8th
edition. Springer, Chicago IL, 2017.
|
|
10
|
Dall'Olio FG, Maggio I, Massucci M,
Mollica V, Fragomeno B and Ardizzoni A: ECOG performance status ≥2
as a prognostic factor in patients with advanced non-small cell
lung cancer treated with immune checkpoint inhibitors-a systematic
review and meta-analysis of real world data. Lung Cancer.
145:95–104. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
U.S. Department of Health and Human
Services, National Institutes of Health, National Cancer Institue:
Common Terminology Criteria for Adverse Events (CTCAE)[J/OL].
http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
|
|
12
|
Rossi A, Di Maio M, Chiodini P, Rudd RM,
Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, et al:
Carboplatin- or cisplatin-based chemotherapy in first-line
treatment of small-cell lung cancer: The COCIS meta-analysis of
individual patient data. J Clin Oncol. 30:1692–1698.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Antonia SJ, Lopez-Martin JA, Bendell J,
Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F,
et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent
small-cell lung cancer (CheckMate 032): A multicentre, open-label,
phase 1/2 trial. Lancet Oncol. 17:883–895. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ott PA, Elez E, Hiret S, Kim DW, Morosky
A, Saraf S, Piperdi B and Mehnert JM: Pembrolizumab in Patients
With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase
Ib KEYNOTE-028 Study. J Clin Oncol. 35:3823–3829. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chung HC, Piha-Paul SA, Lopez-Martin J,
Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D,
Gottfried M, et al: Pembrolizumab after two or more lines of
previous therapy in patients with recurrent or metastatic SCLC:
Results from the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac
Oncol. 15:618–627. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Spigel DR, Vicente D, Ciuleanu TE,
Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N,
Juan-Vidal O, Cheng Y, et al: Second-line nivolumab in relapsed
small-cell lung cancer: CheckMate 331*. Ann Oncol.
32:631–641. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Owonikoko TK, Park K, Govindan R, Ready N,
Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker
M, et al: Nivolumab and ipilimumab as maintenance therapy in
extensive-disease small-cell lung cancer: CheckMate 451. J Clin
Oncol. 39:1349–1359. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rudin CM, Awad MM, Navarro A, Gottfried M,
Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang
JC, et al: Pembrolizumab or placebo plus etoposide and platinum as
first-line therapy for extensive-stage small-cell lung cancer:
Randomized, double-blind, phase III KEYNOTE-604 study. J Clin
Oncol. 38:2369–2379. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yi M, Jiao D, Qin S, Chu Q, Wu K and Li A:
Synergistic effect of immune checkpoint blockade and
anti-angiogenesis in cancer treatment. Mol Cancer.
18(60)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
De Palma M, Biziato D and Petrova TV:
Microenvironmental regulation of tumour angiogenesis. Nat Rev
Cancer. 17:457–474. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li
L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and
antitumor properties of anlotinib, an oral multi-target tyrosine
kinase inhibitor, in patients with advanced refractory solid
tumors. J Hematol Oncol. 9(105)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L,
Han B, Chen G, He J, Wang J, et al: Effect of prior thoracic
radiotherapy on prognosis in relapsed small cell lung cancer
patients treated with anlotinib: A subgroup analysis of the ALTER
1202 trial. Transl Lung Cancer Res. 10:3793–3806. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wu D, Nie J, Hu W, Dai L, Zhang J, Chen X,
Ma X, Tian G, Han J, Han S, et al: A phase II study of anlotinib in
45 patients with relapsed small cell lung cancer. Int J Cancer Dec.
15:3453–3460. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nan X, Xie C, Zhu Q, Zhang J, Fu S, Han X,
Zhang Q, Han B and Liu J: Hand-foot syndrome and survival in
patients with advanced non-small-cell lung cancer receiving
anlotinib: A subgroup analysis of data from the ALTER 0303 study.
Int J Clin Oncol. 25:1492–1498. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen
J, Li J, Shi YR, Jin F, Xu R, et al: Toripalimab or placebo plus
chemotherapy as first-line treatment in advanced nasopharyngeal
carcinoma: A multicenter randomized phase 3 trial. Nat Med.
27:1536–1543. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Duan S, Zhang X, Wang F, Shi Y, Wang J and
Zeng X: Coexistence of oral mucous membrane pemphigoid and
lichenoid drug reaction: A case of toripalimab-triggered and
pembrolizumab-aggravated oral adverse events. Oral Surg Oral Med
Oral Pathol Oral Radiol. 132:e86–e91. 2021.PubMed/NCBI View Article : Google Scholar
|
